Eisai announced that Lenvima (lenvatinib) is now available through two specialty pharmacies, Accredo and Biologics Inc. for the treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC).
Lenvatinib is an oral receptor tyrosine kinase inhibitor with a unique binding mode that selectively inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors, in addition to other proangiogenic and oncogenic pathway-related tyrosine kinases thought to be involved in tumor proliferation.
RELATED: Lenvima Approved for RAI-Refractory Differentiated Thyroid Cancer
Lenvima is available as 4mg and 10mg strength capsules in a carton of six 5-day blister cards.
For more information call (888) 422-4743 or visit Eisai.com.
